A new asset in contraception: E4 14.2 mg + DRSP 3 mg - European Medical Journal

A new asset in contraception: E4 14.2 mg + DRSP 3 mg

EMG-Health | Bonus Episode

Oral contraception is a great asset in family planning that leads to female empowerment. In this podcast, three leading experts from the field of gynecology and haemostasis Kristina Gemzell Danielsson, Diana Mansour and Jonathan Douxfils discuss the brief history and development of combined oral contraceptives and talk about access to contraception during the COVID-19 pandemic. They will also have a discussion about the present situation of VTE risk and combined hormonal contraception and will present data on effect on haemostasis parameters of the estetrol 14.2 mg and drospirenone 3.0 mg combination (14.2 mg estetrol as 15.0 mg estetrol monohydrate).

Spotify | Apple | Download MP3 (mp3, 48:07 mins)

 

The publication of this podcast was funded by Gedeon Richter. The discussion represents the opinion of the speakers and was not influenced by Gedeon Richter. The information contained in this podcast is solely for healthcare professionals and is not for an audience without the relevant education. It is not intended as, and shall not be understood or construed as, medical or health advice.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given